Dysregulated plasma autoantibodies are associated with B cell dysfunction in young Arab children with autism spectrum disorder in Qatar.
Eight blood autoantibodies spot ASD severity in Arab preschoolers, linking immune trouble to symptom strength.
01Research in Context
What this study did
Doctors in Qatar drew blood from preschool Arab children with autism. They measured eight autoantibodies and B-cell counts. The goal was to see if these markers track how severe the autism is.
What they found
Kids with ASD had a unique antibody fingerprint. An eight-marker panel sorted severity with 94% accuracy. Higher antibody levels matched worse social and communication scores.
How this fits with other research
Braunschweig et al. (2012) first tied maternal antibodies to autism risk. Andrews et al. (2024) now show the child’s own antibodies matter too.
Peters et al. (2013) found only moms had brain-reactive antibodies in Spain. The new study shows children themselves carry similar signals in Qatar.
Vargason et al. (2018) tried plasma amino acids for ASD screening but hit only 70% accuracy. The antibody panel beats that by a wide margin.
Why it matters
You can’t run a blood test in clinic yet, but the data say immune markers line up with behavior. Watch for future kits that could flag severity fast and cheap. Until then, note immune issues in your assessments—they may explain mood or sleep swings you see during sessions.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add a quick parent question about frequent infections or allergies; flag kids with both immune and behavior issues for medical follow-up.
02At a glance
03Original abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interaction and communication, as well as the occurrence of stereotyped and repetitive behaviors. Previous studies have provided solid evidence of dysregulated immune system in ASD; however, limited studies have investigated autoantibody profiles in individuals with ASD. This study aims to screen plasma autoantibodies in a well-defined cohort of young children with ASD (n = 100) and their matched controls (n = 60) utilizing a high-throughput KoRectly Expressed (KREX) i-Ome protein-array technology. We identified differential protein expression of 16 autoantibodies in ASD, which were correlated with differential gene expression of these markers in independent ASD cohorts. Meanwhile, we identified a distinct list of 33 autoantibodies associated with ASD severity; several of which were correlated with maternal age and birth weight in ASD. In addition, we found dysregulated numbers of circulating B cells and activated HLADR+ B cells in ASD, which were correlated with altered levels of several autoantibodies. Further in-depth analysis of B cell subpopulations revealed an increased frequency of activated naïve B cells in ASD, as well as an association of resting naïve B cells and transitional B cells with ASD severity. Pathway enrichment analysis revealed disrupted MAPK signaling in ASD, suggesting a potential relevance of this pathway to altered autoantibodies and B cell dysfunction in ASD. Finally, we found that a combination of eight autoantibodies associated with ASD severity showed an area under the curve (ROC-AUC) of 0.937 (95% CI = 0.890, 0.983; p < 0.001), which demonstrated the diagnostic accuracy of the eight-marker signature in the severity classification of ASD cases. Overall, this study determined dysregulated autoantibody profiles and B cell dysfunction in children with ASD and identified an eight-autoantibody panel for ASD severity classification.
Autism research : official journal of the International Society for Autism Research, 2024 · doi:10.1002/aur.3235